Researchers at the Brigham and Women's Hospital found that continuity in color and shape have a significant impact on whether patients stick with a prescription regimen.
Patients want to do more with mobile and see doctors less. Two studies outline the types of digital interventions patients are interested in.
Researchers found a correlation between patients feeling involved and how well they stick—if they stick—to their medication regimens.
A survey of patients found greater prescription drug adherence among patients who received a free 30-day sample in addition to a prescription.
A study showed that side-effect fears keep asthmatics from sticking to medication regimens.
A young company is hoping its analytics platform can help doctors and pharma figure out who's going to stop taking their medication, and get them back on track.
Novo's global diabetes study finds that only 29% of polled patients were asked what they thought about prescribed regimens.
A study points out barriers to e-prescribing pharma products and shows how doctors rate various EHRs.
A study shows consumers are increasingly pleased with retail pharmacies, compared to mail order pharmacies, which are often considered a key means of driving adherence and lowering healthcare coverage costs.
A roundup of some exchange-related news circling the web.
Researchers say using additional data points offers greater insight into patient-adherence patterns.
Gilead in an other sofosbuvir IP fight; study says patients not sticking with Amgen's Brilinta; AstraZeneca and Cytokinetics drug fails to hit Phase II target; Otsuka gets a CRL
Eisai uses a lawsuit to prompt the DEA, AHRQ gets a new director, mWellness runs into adherence issues.
Proteus Digital Health's ingestible sensor shows utility as an adherence tool for those on psych meds, a study suggests.
Three studies take on different angles of the patient experience. Spoiler alert: no cost increases are mentioned.
For a country bent on healthcare cost control, findings represent an opportunity: authors say nearly 8% of the nation's total outlay could have been avoided.
Eisai brings Belivq to 20,000 US pharmacies, along with 200 sales reps and a physician marketing push.
Jolie takes on cancer awareness role, researchers identify another adherence gap, Sanofi gets slapped for scare tactics, Teva may compete for Adcock, AbbVie R&D chief leaves
Two studies released show that the story behind lower consumer healthspend isn't about generics improving health.
Baxter's Alzheimer's treatment is out of the running; Eli Lilly has upped its layoffs; insured consumers are spending less on healthcare; stains and prostate cancer may have an amicable relationship; doctors aren't screening teens for HIV.
Two studies show that it's not enough to focus on cost to alter healthcare.
CDC figures suggest patients are avoiding medications to save money, and show that out-of-pocket costs for US consumers are rising faster than those for consumers in many other countries
Walgreens retail clinics expand diagnostic services, Pfizer says OTC is staying put, Roche-BMS melanoma drug mix runs into PHI troubles.
The EpiduoTap app offers rewards for sticking with the acne-controlling medication.
An adherence study found that when doctors laid out the whys and hows of prescribed medications, patients were more likely to take them. Other reports suggest that the communication gap is about more than the medication— including such factors as pricing, a desire for control, and undisclosed medical information.
Taking a page from Sanofi, Shire is preparing to launch a developer challenge "to create technology driven solutions that aid individuals with ADHD during the transition from adolescence into adulthood."
A study on the effect that a medication's color and shape have on adherence gives short shrift to the marketing component that urges patients not to take medications that don't conform to doctors' orders
The nonpartisan Congressional Budget Office is tallying medical savings differently, adding a new perspective to chatter about the financial implications of nonadherence and rising drug prices.
The amount of revenue pharma leaves on the table due to non-adherence is much more than previously thought, a new study suggests.
The drugmakers bring in a life coach to help COPD patients cope.